Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

In the 1990s, Lotte Bjerre Knudsen, a Novo Nordisk researcher who previously ... measured when we define obesity according to body mass index is not the aspect of overweight that is relevant ...

In the 1990s, Lotte Bjerre Knudsen, a Novo Nordisk researcher who previously studied detergent ... suggesting that what is measured when we define obesity according to body mass index is not the ...

Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk (NVO) announced that the Food and ... along with its existing indications for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major cardiovascular ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

The glycemic index is a measure used to determine how much a food can affect your blood sugar levels. Several factors affect the glycemic index of a food, including the ripeness, nutrient ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

While Novo’s type 2 diabetes GLP-1 Ozempic has largely stolen the show in recent years, obesity med Wegovy—which utilizes the same molecule semaglutide at higher doses than Ozempic ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...